Bath & Body Works Inc. (NYSE: BBWI), a provider of personal care and home fragrance products, on Monday reported an increase in net sales for the third quarter of 2024.
- The company reported net sales of $1.61 billion for Q3, higher than the $1.56 billion reported in the year-ago quarter
- On an adjusted basis, third-quarter earnings per share increased to $0.49 from $0.48 in the same period of fiscal 2023
- Net income, including special items, came in at $106 million in the October quarter, compared to $119 million in the corresponding period last year
- On a per-share basis, reported earnings decreased to $0.49 in Q3 from $0.52 in the prior-year quarter
- For the fourth quarter, the company expects net sales to decline between 6.5% and 4.5%, compared to $2.91 billion last year
- Q4 earnings, on a per-share basis, are expected to be between $1.94 and $2.07, compared to $2.55 in the fourth quarter of 2023
- For fiscal 2024, the management expects net sales to decrease 2.5-1.7%, vs. $7.43 billion in fiscal 2023
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Agentforce in focus as Salesforce (CRM) gets ready for Q3 2025 earnings
After delivering mixed results in the first half, Salesforce, Inc. (NYSE: CRM) looks poised to report strong numbers when it publishes third-quarter results next week. The Customer relationship management platform
What to look for when Dollar Tree (DLTR) reports Q3 2024 earnings
Shares of Dollar Tree, Inc. (NASDAQ: DLTR) rose over 5% on Monday. The stock has dropped 27% over the past three months. The discount store chain is scheduled to report
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
